Sirona Biochem Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Howard J. Verrico
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 595 Burrard Street Vancouver BC Canada V7X 1L4
- IPO Date
- Feb 12, 2013
- Website
- sironabiochem.com
- Similar Companies
- Business
- Sirona Biochem Corp is a biotechnology company specializing in the discovery and development of stabilized carbohydrate-based molecules for cosmetic and therapeutic applications. The company’s proprietary chemistry technology enhances the stability and efficacy of carbohydrate molecules, which are inherently unstable. Its main products include cosmetic and dermatology active ingredients such as TFC-1067, a dark spot corrector licensed to Rodan + Fields; TFC-1326, an anti-aging compound; and a pipeline featuring anti-wrinkle, cellulite treatment, and anti-viral programs. Sirona also develops glycoprotein libraries aimed at cell protection and anti-aging applications. The company operates primarily through its subsidiary TFChem in France and targets global cosmetic and therapeutic markets. Founded in 2011 and headquartered in Vancouver, Canada, Sirona Biochem has executed significant strategic initiatives recently. In 2025, it secured a $3 million CAD convertible debenture financing and formed a strategic partnership with German-based Promura GmbH to establish Sirona Laboratories in Luxembourg, focusing on dermatological and cosmetic innovation with emphasis on commercializing the anti-aging product line. Despite this, financial pressures led to a cease trade order in March 2025, and Sirona initiated the liquidation and permanent closure of its TFChem laboratory subsidiary. Additionally, Allergan Aesthetics withdrew from a prior license agreement for the TFC-1067 compound. The company continues to evaluate options for future development while focusing on its innovative portfolio with 83 approved and pending patents globally. Sirona Biochem’s product offerings cover active ingredients for cosmetic skin lightening, anti-aging, anti-wrinkle, scar therapies, and cell preservation, with regulatory and clinical steps underway for their market launch. Its developments include partnerships and licensing agreements with leading skincare brands to commercialize proprietary compounds. The company’s strategic focus remains on positioning its stabilized carbohydrate technologies for maximum commercial potential across cosmetic and therapeutic skincare sectors worldwide.
Sirona Biochem Update to Shareholders on Financial Status and Operations
Sirona Biochem Announces Debenture Financing
Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH
Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare's Landmark Report
Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology
SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout
GlycoProteMim Featured in Stonegate Healthcare's Latest Anti-Aging Research Report
SIRONA BIOCHEM Corporate Update April 2024
Sirona Biochem Announces Close of Private Placement
Sirona Biochem Announces 2023 Annual Meeting Results
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025
Sirona Biochem Provides Update on Loan
Sirona Biochem Engages Global Beauty Consulting
Sirona Biochem Announces Loan
Sirona Biochem Initiates Private Placement
CORRECTION -- Sirona Biochem Corporate Update January 2024
Sirona Biochem Corporate Update January 2024
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™
Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326